Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Developing talent in the fast-changing clinical research environment

2
November 2021

In a feature article for PharmaTimes, Dr. Ulrike Lorch, Medical Director at Richmond Pharmacology, outlines how investing in the clinical research workforce is crucial to delivering high quality, cutting-edge trials and achieving faster drug development

View Articles

Focal epilepsy treatment progresses following positive Phase IIb results

26
October 2021

Richmond Pharmacology’s research partner, Xenon Pharmaceuticals reported positive top line results from its Phase IIb X-TOLE clinical trial of XEN1101 – a differentiated Kv7 potassium channel modulator.

View Articles

The future of new medicine development and first-in-human studies

26
October 2021

Dr Jorg Taubel outlines the future of new medicine development, influenced by the emergence of gene based therapies and reshaping first-in-human study design.

View Articles

Making gains in drug development

2
September 2021

Keith Berelowitz outlines the innovations in the design and delivery of clinical trials

View Articles

Inclisirin hailed as a 'gamechanger' gains approval for NHS patients

2
September 2021

This novel therapeutic drug has potential to impact millions at risk of heart attack and stroke.

View Articles

Richmond Pharmacology listed in the Alantra Pharma Fast 50

13
July 2021

Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 

View Articles

Latest news

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Events

HFA 2025

17–20 May 2025
Richmond Pharmacology will participate in HFA 2025 in Belgrade from 17–20 May, focusing on heart failure research, clinical trials, and scientific collaboration.
View event